Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis

Background Cabergoline is a recommended first-line dopamine agonist for prolactinoma treatment, which is withdrawable for some cases. However, the optimal withdrawal strategy and the accurate recurrence rate associated with cabergoline withdrawal remains uncertain.